ALNYLAM PHARMACEUTICALS, INC.
Pharmaceutical Preparations- 売上
- $3.7bn
- 時価総額
- $26.6bn
株価 $205.48 · 100株 2万円
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $1.8bn | $2.2bn | $3.7bn |
| 成長率 | — | 23.0% | 65.2% |
| 総利益 | $1.6bn | $1.9bn | $3.0bn |
| 総利益率 | 85.3% | 86.4% | 81.8% |
| 販管費 | $796m | $976m | $1.2bn |
| 販管費率 | 43.5% | 43.4% | 32.6% |
| 営利 | ▲$282m | ▲$177m | $502m |
| 営利率 | ▲15.4% | ▲7.9% | 13.5% |
| 純利益 | ▲$440m | ▲$278m | $314m |
| PBR | — | 396.5 | 33.7 |
| PSR | 14.5 | 11.8 | 7.2 |
| PGPR | 17.1 | 13.7 | 8.8 |
| PER | — | — | 85 |
| ネットキャッシュ | $813m | $966m | $1.7bn |
| EV/EBITDA | — | — | 44.8 |
| Rule of 40 | — | 15% | 79% |
| セールス効率 | — | 212% | 466% |
※Rule of 40は売上成長率+営業利益率、セールス効率は売上総利益増加÷販管費増加(販管費増のときのみ)
